Share on StockTwits

Radius Health (NASDAQ:RDUS) released its earnings data on Tuesday. The company reported ($2.22) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.89) by $1.33, American Banking News.com reports. The company had revenue of $10.62 million for the quarter, compared to the consensus estimate of $16.24 million.

A number of research firms have recently commented on RDUS. Analysts at Cowen and Company initiated coverage on shares of Radius Health in a research note on Wednesday, July 16th. They set an “outperform” rating on the stock. On the ratings front, analysts at Cantor Fitzgerald initiated coverage on shares of Radius Health in a research note on Wednesday, July 16th. They set a “buy” rating and a $20.00 price target on the stock. Finally, analysts at Canaccord Genuity initiated coverage on shares of Radius Health in a research note on Wednesday, July 16th. They set a “buy” rating and a $21.00 price target on the stock.

Shares of Radius Health (NASDAQ:RDUS) opened at 12.64 on Tuesday. Radius Health has a 52-week low of $7.46 and a 52-week high of $17.32. The stock has a 50-day moving average of $11.31 and a 200-day moving average of $10.60. The company’s market cap is $365.8 million.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.